Advertisement
Biogen Inc.

Biogen Inc. (BIIB) Stock Overview

Explore Biogen Inc.’s financial performance, market position, analyst ratings, and future outlook.

BIIBNASDAQ
HealthcareDrug Manufacturers - General
$216.03
$14.07(6.97%)
U.S. Market opens in 43h 26m
Advertisement

Biogen Inc. (BIIB)

Meyka AI Score

Z

Key Financials

Market Cap31.9B
P/E Ratio22.68
EPS (TTM)$15.84
ROE0.08%
Fundamental Analysis

AI Price Forecasts

1 Month$203.02
3 Months$221.72
1 Year Target$136.44

BIIB Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Biogen Inc. (BIIB) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 69.71, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $136.44.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 22.68 and a market capitalization of 31.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
6.97%
5-Day Change
8.30%
1-Month Change
11.89%
3-Month Change
13.07%
6-Month Change
22.00%
Year-to-Date (YTD) Change
22.75%
1-Year Change
70.21%
3-Year Change
-23.28%
5-Year Change
-36.51%
All-Time (Max) Change
6812.96%

Contact Information

617 679 2000
225 Binney Street, Cambridge, MA, 02142

Company Facts

76,050 Employees
IPO DateSep 17, 1991
CountryUS
Actively Trading

Frequently Asked Questions